Continuing Education Activity
This activity reviews the minimally invasive medical therapy known as uterine artery embolization (UAE). It discusses which patients may or may not benefit from this therapy. It reviews how an interprofessional team works together for these patients.
Objectives:
Know indications, contraindications, and possible alternatives to UAE.
Explain patient preparation and some of the procedural technique for UAE.
Identify known complications of UAE.
Recognize clinical benefits that can be achieved by UAE with the help of an interprofessional team evaluating, treating, and educating the patient on the procedure.
Access free multiple choice questions on this topic.
Introduction
Embolization of uterine leiomyomata (fibroids) has been performed since 1995. Because the embolization procedure is performed either solely or primarily through the uterine artery, the procedure is often referred to as uterine artery embolization (UAE). Some authors prefer to refer to the procedure as uterine fibroid embolization or UFE, but UAE has indications other than for treatment of fibroids, so the term UAE is preferred here.
The procedure's technical success is defined as delivery of the embolic particles to their intendend distention. Technical success of bilateral UAE by experienced physicians is about 95%.
The goal of therapy is to relieve symptoms, and not all women whose procedures are deemed to be a technical success remain symptom free, as discussed later. Symptom improvement from fibroid tumor therapy is correlated with tumor death. A retrospective review of 84 fibroids treated over one year showed an average decrease in the size of 60%. Submucosally located fibroids showed the greatest shrinkage, while subserosally located fibroids showed the least. Ten percent of the fibroids increased in size.[1][2][3]
Anatomy and Physiology
The uterine artery is a branch of the internal iliac artery (IIA). The IIA has two divisions, each with multiple branches:
Anterior Division
Variations in this organization can occur. For example, the vaginal artery may arise from the uterine artery itself.
Posterior Division
Superior gluteal artery
Lateral sacral artery
Iliolumbar artery
The uterine artery is typically the first branch of the IIA anterior division, whereas the dominant (largest) branch of the IIA anterior division is usually the inferior gluteal artery. Five distinct IIA branching patterns have been described. The most common is as described above. The second most common is a trifurcation of the IIA into the UA, the IIA anterior division, and the IIA posterior division.
The UA has three segments. Its first segment descends along the pelvic sidewall to the broad ligament. The second segment courses transversely toward the abdominal midline. As it reaches the uterus, it again turns, and the third segment ascends the uterine sidewall. Thus, the segments are termed the descending, transverse, and ascending segments. The descending segment has no side branches. A branch termed the cervicovaginal branch usually arises from the mid to distal transverse segment, but it can arise from the ascending segment. From the ascending segment, numerous branches course over the surface of the uterus and in turn give rise to numerous arterioles that perforate the myometrium. Arterioles supplying individual fibroids are usually too small to be seen or to be catheterized.
Communication (anastomosis) between the UA and the ovarian artery (OA) can be demonstrated in almost half of female cadavers, but during angiography this anastomosis is visible about 10% of the time. A classification for OA-UA anastomoses has been proposed.
Flow from the OA into the descending or transverse UA is the most common (type 1).
An OA branch can bypass the main UA to an ascending UA branch supplying a fibroid (type 2).
In about 1 out of 20 women, an OA is absent, and the ovary itself is supplied by the UA (type 3).
Conversely, the OAs (instead of the IIA) rarely can supply the uterus directly with no UA derived from the IIA (which is not alotted a type number but is similar to type 1). There are other rarer variants as well. The OAs typically arise from the aorta a few centimeters below the origins of the renal arteries. Their courses are often too tortuous to insert a standard catheter for more than a few centimeters. The importance of the OAs in the management of patients underoing embolization is discussed below.
Indications
The success of UAE depends on appropriate patient selection, which requires an investigation of multiple pertinent positive and negative factors. [4][5] Patient symptom control and post-procedure satisfaction are highest in "ideal" candidates, which are women with no contraindications to UAE and with all of the following characteristics:
Fibroids characteristically cause heavy bleeding cycles, not irregular bleeding. Increased frequency of bleeding (fewer than 21-day cycles) and increased duration of bleeding (greater than 10 days) are more likely to be related to endometrial pathologies such as polyps or cancer.
Instead of or in addition to bleeding, fibroids can cause "bulk-related" symptoms:
The sensation of pressure in the lower abdomen, legs, and back
Dysuria (i.e., nocturia, polyuria, incontinence)
Prospective cohort studies and randomized controlled trials (RCT) of women who have undergone UAE have found a long-term improvement in bulk-related symptoms, [5][6] but bulk-related symptoms in general are not as successfully treated as bleeding.
There are other indications for UAE.
Adenomyosis
A retrospective review reported that 76% of 511 women having undergone UAE for the treatment of adenomyosis reported significant improvement, [7] and other studies with smaller patient groups have also claimed high rates of improvement. However, there has not yet been a study that has included a control group to account for a placebo effect or to enable determination of a number needed to treat (NNT). Patients with adenomyosis can also complain of worsened pain after UAE.
Postpartum Hemorrhage (PPH)
Whether UAE is viewed as the first or second line treatment (i.e., after incomplete/ineffective surgical ligation) for PPH tends to be institution and/or gynecologist dependent. Factors predicting the need for UAE as the first line before surgery include abnormal placental attachment and abnormal clotting function (e.g., as determined by serum fibrinogen/INR). Performing UAE after a failed uterine artery ligation is more difficult.
Persistent bleeding after surgical treatment can indicate the source of bleeding to be an extrauterine arterial source that may be better identified with arteriography. In one case series, arterial embolization was successful in 10 of 11 cases after failed surgical ligation therapy.
Prophylaxis of Intra-Operative or Post-Operative Bleeding
In some institutions, gynecologists request UAE as a prophylactic measure in an attempt to reduce operative hemorrhage, such as for:
Failed Medical Therapy or Poor Candidate for Other Therapies for Fibroids
UAE also becomes a relevant consideration if a patient without contraindications to the procedure declines or has already attempted other therapies to treat bleeding or pelvic bulk symptoms (e.g., hysterectomy, myomectomy, endometrial ablation, gonadotropin-releasing hormone agonists, or focused ultrasound).
An in-depth discussion of medical treatment for fibroids and abnormal uterine bleeding is beyond the scope of this article, but a brief overview is included here. A Cochrane database meta-analysis of randomized trials concluded that nonsteroidal anti-inflammatory drugs are more effective than placebo at decreasing menstrual pain and heavy menstrual bleeding but are less effective than tranexamic acid or the levonorgestrel-releasing IUD than placebo.
Gonadotropin-releasing hormone analogues (GnRHa) can shrink fibroids and limit menorrhagia but usually initially worsen symptoms. Because they cause osteopenia with long term use, GnRHa can only be used for 2 to 6 months and when there is a clear therapeutic goal such as scheduled surgery or when menopause is incipient (Friedman 1991).
Gonadotropin-releasing hormone antagonists (GRHa) avoid the symptom flare that is associated with GnRHa but also cause osteopenia with long term use. Rebound fibroid growth occurs after cessation of both GnRHa and GRHa.
Randomized trials have shown that the progesterone-receptor antagonists (PRa) mifepristone and ulipristal acetate decrease fibroid symptoms and reduce fibroid volume without osteopenia. A woman undergoing therapy with a PRa cannot become pregnant, which is a goal for some women simultaneously wanting therapy for fibroids.
Contraindications
Different organizations have different lists of "absolute" and "relative" contraindications to UAE. The following list roughly orders contraindications from strongest to weakest.[4]
Viable active pregnancy
Active endometritis
Malignancy of the uterus/cervix without concurrent surgical treatment planned
Postmenopausal patient with bleeding of undiagnosed etiology
Fibroid that is already infarcted (based on MRI)
Fibroid that is smaller than 1 cm
Fibroid with pedunculated morphology (such as stalk width less than 50% of the maximum width; some people use different percentage cutoffs)
Fibroid located in the cervix
Concurrent use of a GnRH agonist
Prior pelvic radiation therapy
Immunocompromised state
Fibroid growth resulting in overall uterus size equivalent or greater than the expected size at 24 weeks gestation (uterus craniad aspect reaching the umbilicus)
Severe contrast allergy
Severe renal insufficiency not receiving dialysis therapy
Uncorrectable coagulopathy
Of some controversy:
For both of these topics, the 2014 SIR guidelines state that in the absence of further evidence, neither should be seen as a contraindication but only as a point of discussion. The 2009 SIR guidelines listed patient desire for future pregnancy as a relative contraindication and were ambivalent on adenomyosis, only stating that "extensive endometriosis or adenomyosis" could result in UAE failure. Evidence regarding these issues is discussed elsewhere in this article.[8][9][10]
Gonadotropin-releasing hormones that may have been prescribed as medical therapy should be stopped at least three months before UAE because they constrict the uterine arteries and may preclude their catheterization.
If the stalk of a pedunculated fibroid is much less than the overall fibroid diameter, then laparoscopic resection can avoid the chance of the fibroid sloughing and forming a loose necrotic tissue mass in the abdomen that can become infected and form an abscess. A fibroid that is very large and has an extensive blood supply is unlikely to be successfully embolized, whereas a fibroid that is very small is unlikely to be the source of symptoms. Fibroids of the cervix are often able to be removed surgically via a vaginal approach.
Equipment
In general, tumors are embolized with particles, which are more likely than coils or glue to reach arterioles and capillaries and induce tissue necrosis. Several types of particles are available, including tris-acryl gelatin (TAG) spheres, non-spherical polyvinyl alcohol (PVA), and spherical PVA.
Regarding the size of particles used, no clinical difference was found between the use of 500 micron or smaller PVA compared to 500 to 700 micron PVA particles in a RCT. However, it is generally believed that smaller particles result in better infarction rates. This can be desireable or undesireable depending on the situation, because particles can reflux within an artery and cause "inadvertent" embolization of other nearby tissues (such as the ovary). Therefore, large (700 to 900 micron) particles may be chosen if there is a visualized ovarian artery anastomosis, whereas small (300 to 500 micron) particles may be chosen when the microcatheter has been successfully placed deep within the uterine artery without a visualized uterine artery-ovarian artery anastomosis to attempt better fibroid infarction. A RCT comparing TAG microspheres to nonspherical PVA particles found no difference in short-term clinical outcomes. A follow-up RCT by the same physicians found a statistically significant increase in fibroid infarction rates with TAG compared to PVA and a trend toward improved short-term clinical outcome with TAG. A third RCT comparing PVA and TAG had eight treatment failures in 27 patients with PVA and one treatment failure in 26 patients TAG, but the physicians used smaller particle sizes for TAG than for PVA, and the study was performed under the conflict of interest that the TAG manufacturers paid for the study. There has not been a RCT comparing clinical symptoms after using TAG and PVA of the same size particles. [11][12][13][14][15]
Preparation
The possible causes of the symptoms should be investigated in order to exclude pathologic or anatomic contraindications to UAE (as discussed above).
Cancer Screening
The patient should be current in her gynecologic screening for cervical cancer. American College of Obstetrics and Gynecology (ACOG) recommendations include HPV testing at age 30 thereafter every 3 years if a woman is HPV-positive and every 5 years if HPV-negative. Papanicolaou smears are not recommended after age 65 unless there is a special reason to continue. Women with any endometrial abnormalities on imaging, particularly women over age 45, should undergo endometrial biopsy before UAE, because UAE is not an approved therapy for the treatment of endometrial cancer.
Serum Parameters to Evaluate
Electrolytes
Estimated glomerular filtration rate (eGFR)
Complete blood count (CBC)
Platelet count greater than 50,000 per microliter
International normalized ratio (INR) less than or equal to 1.5
Beta-human chorionic gonadotropin for pregnancy exclusion
Imaging
MRI provides a significant amount of additional information compared with ultrasound (size and position of fibroids, adenomyosis status) and should be performed prior to UAE.
Informed Consent
The 2009 SIR guidelines stress the importance of informed consent before UAE:
"Any and all treatment options should be presented with the understanding that, for patients interested in gynecologic alternatives, additional consultation will be required. Choice of embolic agents, routes of vascular access, and the anticipated use of an arterial closure device should be discussed. Descriptions of the expected process of admission to the hospital (and by whom), the immediate post-uterine artery embolization recovery period, convalescence and medications at home, and the time expected away from work should also be made.
Written materials given at the time of consultation can enhance this process. Contact information should be given to patients so they can access a responsible physician on a 24-hour availability basis if they perceive that a problem has arisen." [15]
The 2014 SIR guidelines state:
"Interventional radiologists should inform patients about...the possibility of a missed diagnosis of cancer and a delay in definitive treatment." [16]
These recommendations are set with the intention to preserve patients' rights of autonomy.
Pre-Procedure Care
Blood-borne pathogens can colonize UAE-induced necrotic tissue. The 2018 SIR guidelines recommend that antibiotics, such as 1 g cefazolin or 500 mg levofloxacin, be given IV to reduce the chance of abscess development. [17]
Some physicians prescribe pain medication (e.g., ketorolac 30 mg IV) prior to the procedure.
If the patient has risk factors for a difficult-to-intubate airway (e.g., screens positive on a sleep apnea questionnaire), then precautions should be taken (e.g., having the patient monitored by capnography at all times) to prevent arrest from respiratory depression from sedation. Some states have laws requiring capnography, and the 2013 SIR standards of practice recommend it. [18]
Post-Procedure Care
There are a number of clinical factors that may need to be addressed after the procedure.
Pain
Options for management include NSAIDs and/or opioids.
One regimen includes:
Ketorolac 30 mg given before the procedure and after, then 30 mg every 6 hours intravenously (IV) as an inpatient
Ibuprofen scheduled during post-procedure observation and opioid of choice available PRN for several days after discharge
Puncture site pain or leg pain is common, which can be from injury of the medial femoral cutaneous nerve. It usually responds to NSAIDs and time. For severe pain thought to be related to nerve injury, gabapentin can be prescribed.
If a patient has persistent (longer than 1 week) abdominopelvic pain, then imaging workup for non-target embolization should be considered.
Chronic pain syndromes (such as inflammatory bowel disease) may worsen after UAE.
Pulmonary Emboli Prevention
Sequential compression devices and prophylactic enoxaparin should be considered. Patients have developed and died from pulmonary emboli after UAE.
Bleeding
Vaginal bleeding in the first week after therapy could indicate a developing endometrial infection. A patient with endometritis should have flu-like symptoms and fever. Bleeding after the first week with cramping could indicate that there is a sloughing or sloughed fibroid.
Nausea
Nausea can be treated with ondansetron 4 mg IV after the procedure continued every 6 hours until discharge.
Hypertension
Blood pressure often increases in the short term after embolization. Potential sequelae of hypertension include pulmonary edema, myocardial infarction, and stroke.
Post Discharge Communication
Communication between the patient and the physician or physician representative should continue during the first week. Physicians may wish to schedule a return clinic visit at 1 to 3 months.
Technique or Treatment
The technique for UAE is described in brief below:
Access the common femoral artery and insert a 5 or 6 French sheath.
Obtain an arteriogram to demonstrate the arterial anatomy and find the UA origins.
Place a catheter with a selective tip shape into the IIA anterior division.
Advance a smaller catheter (a microcatheter) coaxially through the selective tip catheter and then into the UA horizontal segment beyond any cervicovaginal branch(es).
Obtain another arteriogram through the microcatheter to identify any collateral branch(es) to the ovaries/bladder/vagina that might affect specific choices made in particle delivery.
Perform embolization.
Obtain final images showing the state of intra-arterial contrast flow to the uterus.
Repeat the procedure on the contralateral side.
Obtain hemostasis at the site(s) of the arterial puncture(s).
Variables are many and include:
Bilateral femoral artery punctures (to decrease procedure time) vs. single femoral artery puncture (to decrease the likelihood of artery access site complication)
Initial or final overview arteriogram from the aorta (to identify an OA contribution/variant anatomy) versus only selective common iliac arteriograms (to reduce contrast load)
Delivery of medications during the procedure (such as nitroglycerin to prevent/treat arterial spasm, lidocaine intra-arterially or ketorolac intravenously to reduce post-procedure pain)
Embolization endpoint (contrast stasis in the UA for 5 to 10 heartbeats, versus visualization of contrast reflux toward the UA origin, versus subjectively achieving a UA "pruned" appearance)
Complications
The overall complication rate differs by published report and can be as high as 40% to as low as 5%.[19][20][21]
Major Complications
Death (less than 1/1000)
Need for surgery due to a complication of the procedure, such as arterial perforation (2 to 3 in 100)
Abscess/other serious intrauterine infection (1 in 100)
Pulmonary embolism
Subsequent pregnancy-related complications, such as spontaneous uterine rupture at the mid-posterior wall during subsequent pregnancy or placenta accreta
Premature ovarian failure
Buttock/leg ischemia
Death
Deaths have occurred from UAE via uterine infection/sepsis and pulmonary embolism.
Infection-Spectrum Findings
Postembolization syndrome is the most common adverse event and includes pain, low-grade fever, malaise, nausea, and appetite loss. Symptoms and signs of bacterial endometritis include pain, fever, vaginal discharge, and/or leukocytosis. Initial therapy includes intravenous antibiotics and medications to reduce pain and inflammation. Noninfectious endometritis can manifest as watery vaginal discharge, fever, and/or leukocytosis occurring days to weeks after the procedure. Imaging findings do not reliably differentiate infected fibroids from non-infected fibroids immediately after UAE.
Amenorrhea Spectrum Findings
Amenorrhea of any kind occurs in less than 10% of cases when considering patients treated for all UAE indications and is much more likely in patients older than 45 to 50 years old. It is usually limited to a few cycles and is not typically associated with increased FSH levels or menopausal symptoms. Premature ovarian failure is defined as the presence of persistent amenorrhea, increased FSH levels, and symptoms of menopause (night sweats, mood swings, irritability, and/or vaginal dryness).
Expulsion of Fibroids
Expulsion is defined as a detachment of fibroid tissue from the uterine wall and its subsequent transvaginal passage, most commonly occurring with submucosal fibroids that have thin points of attachment. This process may present with uterine contractions, abdominal pain, fever, nausea, vomiting, and vaginal bleeding or discharge. Surgical intervention may be necessary to relieve persistent discomfort and remove the tissue.
Angiography Complications
These include hematoma, dissection, pseudoaneurysm, and contrast-induced nephropathy.
Complications Other
Patients may have persistent pain. Contrast-enhanced CT or MRI may be used in these circumstances to assess for findings of non-target embolization or for fibroid sloughing into the pelvis.
The radiation doses for UAE are an order of magnitude less than those required to produce radiation burns.
There have been reports of petechial rash on the torso and limbs (1% to 7%) after UAE.
Clinical Significance
For women with ideal procedure selection characteristics, a high symptom control rate, procedure satisfaction rate, and self reported quality of life rate can be achieved for up to 10 years after treatment, as discussed below.
The SIR guidelines indicate that about 90% of women should experience a reduction in bulk symptoms and that more than 90% should expect the elimination of abnormal uterine bleeding.
Causes of UAE failure include but are not limited to:
Poor patient selection
Large fibroids
Inability to catheterize the uterine arteries
Incomplete artery embolization
Arterial spasm leading to poor flow of embolic arterial
Clumping of embolic material leading to false embolization endpoint
Uterus anatomic variants
Presence of important collateral arteries (e.g., ovarian arteries) feeding the uterus
Coexisting adenomyosis or leiomyosarcoma
Recanalization of embolized arteries
Trials and Guidelines for Treatment of Fibroids
There have been seven RCTs including 793 women comparing UAE versus surgery for fibroids. Three trials compared UAE against abdominal hysterectomy, two against myomectomy, and two against either type of surgery. In a meta-analysis of these patients, Gupta et al. (2014) found no significant difference between UAE and any type of surgery concerning patient satisfaction or major adverse events. UAE had a higher rate of minor complications and need for additional surgical interventions. Gupta calculated that within 2 years of initial therapy, 7% of women require further surgery after hysterectomy or myomectomy, whereas 15% to 32% require further surgery after UAE. UAE patients were found to have a lower likelihood of requiring a blood transfusion, shorter procedural time, shorter length of hospital stay, and faster resumption of usual activities.[22]
The first randomized controlled trial (RCT), Embolization versus Hysterectomy for Symptomatic Uterine Fibroids (EMMY), enrolled patients between 2002 and 2004. This multicenter trial has the longest follow-up to date (ten years). Enrolled patients had both fibroids and menorrhagia and were all eligible for hysterectomy. One hundred seventy-seven patients were randomized to UAE (n = 88) or hysterectomy (n = 89). Ten years after treatment, 33% of UAE patients had undergone secondary hysterectomy for recurrent symptoms (8% of initial hysterectomy patients also required a second procedure), but there were no significant differences between hysterectomy and UAE with respect to successful eradication of pain, bulk-specific complaints, complications, or overall satisfaction. The study authors concluded that hysterectomy is better at achieving a certain cure for bleeding problems but that patients with the appropriate combination of indications and lack of contraindications should be allowed to choose UAE instead of a hysterectomy.[23]
The Randomized Controlled Trial of Embolization versus Surgical Treatment for Fibroids (REST) is the largest study to date. It was a multicenter RCT comparing all surgical interventions to UAE and achieved 80% power with 1-year follow-up. It found no statistically significant difference between UAE and surgery in quality of life or major complications. UAE had a higher minor complication rate (34% versus 20%) but also had a statistically significant reduced length of hospitalization, 24-hour pain score, and cost.[24]
In one study, patients having intramural fibroids larger than 4 cm were randomized to UAE (n = 58) or to myomectomy (open or laparoscopic according to surgeon preference; n = 63) and followed for two years. This is the primary study used as the rationale for making myomectomy the first-line invasive therapy in women who still wish to conceive, as 50% of UAE versus 78% of myomectomy patients were able to conceive. UAE in this study had an increased calculated relative risk compared to myomectomy for (1) inability to conceive and (2) miscarriage (95% CI of [1] 1.11 to 4.44 and of [2] 1.25 to 6.22). However, Gupta (2014), included Mara's patients with others having undergone myomectomy in RCTs and deemed the evidence that myomectomy provides a fertility benefit over UAE to be "low-quality evidence" that "should be regarded with extreme caution." Another systematic review on myomectomy concluded that there is currently insufficient evidence that myomectomy improves fertility compared to UAE whether by the laparoscopic or open approach.[22]
A Cochrane systematic review of 15 prospective cohort studies and RCTs found that loss of ovarian function after UAE occurred primarily in women older than 45 years of age.
Despite the conclusions of Gupta (2014), guidelines by gynecological societies in France and the United States recommend myomectomy over UAE for symptomatic intramural and subserosal fibroids in women who wish to have a subsequent pregnancy. In the United Kingdo, the Royal College of Obstetricians and Gynecologists does not have guidelines on the subject, but the British National Institute for Health and Care Excellence guidelines do not favor UAE or surgery over the other even for patients considering future pregnancy.
Trials and Guidelines not for the Treatment of Fibroids
Outside of the setting of treatment of fibroids, there are no RCTs comparing UAE to other treatments and almost no society or national guidelines regarding the use of UAE over other therapies.
For the control of PPH, emergent UAE has about a 90% to 95% success rate (with failures usually requiring hysterectomy), and the morbidity of UAE is less than with emergent laparotomy.
Enhancing Healthcare Team Outcomes
Healthcare Team
Uterine artery embolization is usually performed by an interventional radiologist, but the gynecologist and obstetrician should also be able to help educate the patient about pros and cons of this technique compared to surgical and/or medical treatments that the gynecologist or other primary care physician can offer. The patient should be informed that infertility may result and that subsequent pregnancy may be complicated (such as by premature birth). [25][26](Level V and see above section, Level I). The nurse taking care of the patient post-procedure may have to administer physician-prescribed analgesics and other medications. This nurse also observes for signs of complications, primarily those resulting from arterial puncture.
Outcomes Summary
Most randomized (Level I, see above section) and non-randomized series report high odds of clinical success and subsequent pregnancy success for UAE, although UAE is not necessarily always superior to surgical techniques. UAE is best suited for women who prefer a minimally invasive procedure to surgery or other methods of treatment and are willing to accept the risks of UAE. [27][28]
References
- 1.
Kohi MP, Spies JB. Updates on Uterine Artery Embolization.
Semin Intervent Radiol. 2018 Mar;35(1):48-55. [
PMC free article: PMC5886769] [
PubMed: 29628616]
- 2.
Donnez J, Donnez O, Dolmans MM. The current place of medical therapy in uterine fibroid management.
Best Pract Res Clin Obstet Gynaecol. 2018 Jan;46:57-65. [
PubMed: 29169896]
- 3.
Ierardi AM, Savasi V, Angileri SA, Petrillo M, Sbaraini S, Pinto A, Hanozet F, Marconi AM, Carrafiello G. Percutaneous High Frequency Microwave Ablation of Uterine Fibroids: Systematic Review.
Biomed Res Int. 2018;2018:2360107. [
PMC free article: PMC5817312] [
PubMed: 29511672]
- 4.
Masciocchi C, Arrigoni F, Ferrari F, Giordano AV, Iafrate S, Capretti I, Cannizzaro E, Reginelli A, Ierardi AM, Floridi C, Angileri AS, Brunese L, Barile A. Uterine fibroid therapy using interventional radiology mini-invasive treatments: current perspective.
Med Oncol. 2017 Apr;34(4):52. [
PubMed: 28236104]
- 5.
Solnik MJ, Munro MG. Indications and alternatives to hysterectomy.
Clin Obstet Gynecol. 2014 Mar;57(1):14-42. [
PubMed: 24488051]
- 6.
Cooper S, Oceguera LM, Danes S. Uterine artery embolization: a vascular surgery procedure? One vascular surgery group's experience.
Vascular. 2012 Oct;20(5):268-72. [
PubMed: 22962044]
- 7.
Popovic M, Puchner S, Berzaczy D, Lammer J, Bucek RA. Uterine artery embolization for the treatment of adenomyosis: a review.
J Vasc Interv Radiol. 2011 Jul;22(7):901-9; quiz 909. [
PubMed: 21570318]
- 8.
Stampfl U, Radeleff B, Sommer C, Stampfl S, Dahlke A, Bellemann N, Kauczor HU, Richter GM. Midterm results of uterine artery embolization using narrow-size calibrated embozene microspheres.
Cardiovasc Intervent Radiol. 2011 Apr;34(2):295-305. [
PubMed: 20953610]
- 9.
Volkers NA, Hehenkamp WJ, Birnie E, de Vries C, Holt C, Ankum WM, Reekers JA. Uterine artery embolization in the treatment of symptomatic uterine fibroid tumors (EMMY trial): periprocedural results and complications.
J Vasc Interv Radiol. 2006 Mar;17(3):471-80. [
PubMed: 16567671]
- 10.
Hovsepian DM, Siskin GP, Bonn J, Cardella JF, Clark TW, Lampmann LE, Miller DL, Omary RA, Pelage JP, Rajan D, Schwartzberg MS, Towbin RB, Walker WJ, Sacks D., CIRSE Standards of Practice Committee. SIR Standards of Practice Committee. Quality improvement guidelines for uterine artery embolization for symptomatic leiomyomata.
Cardiovasc Intervent Radiol. 2004 Jul-Aug;27(4):307-13. [
PubMed: 15346204]
- 11.
Expert Panel on Interventional Radiology: Knuttinen MG, Stark G, Hohenwalter EJ, Bradley LD, Braun AR, Gipson MG, Kim CY, Pinchot JW, Scheidt MJ, Sella DM, Weiss CR, Lorenz JM. ACR Appropriateness Criteria
® Radiologic Management of Uterine Leiomyomas.
J Am Coll Radiol. 2018 May;15(5S):S160-S170. [
PubMed: 29724419]
- 12.
Badiani B, Chiumente M, Messori A. Ulipristal acetate for pre-operative management of uterine fibroids: Modeling outcomes and costs.
Eur J Obstet Gynecol Reprod Biol. 2018 Mar;222:84-88. [
PubMed: 29408752]
- 13.
Fonseca MCM, Castro R, Machado M, Conte T, Girao MJBC. Uterine Artery Embolization and Surgical Methods for the Treatment of Symptomatic Uterine Leiomyomas: A Systemic Review and Meta-analysis Followed by Indirect Treatment Comparison.
Clin Ther. 2017 Jul;39(7):1438-1455.e2. [
PubMed: 28641997]
- 14.
Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future.
Hum Reprod Update. 2016 Nov;22(6):665-686. [
PMC free article: PMC5853598] [
PubMed: 27466209]
- 15.
Jiang W, Shen Z, Luo H, Hu X, Zhu X. Comparison of polyvinyl alcohol and tris-acryl gelatin microsphere materials in embolization for symptomatic leiomyomas: a systematic review.
Minim Invasive Ther Allied Technol. 2016 Dec;25(6):289-300. [
PubMed: 27433856]
- 16.
Siskin GP. Quality improvement guidelines for uterine artery embolization: an evolution in patient selection.
J Vasc Interv Radiol. 2014 Nov;25(11):1748-9. [
PubMed: 25442137]
- 17.
Chehab MA, Thakor AS, Tulin-Silver S, Connolly BL, Cahill AM, Ward TJ, Padia SA, Kohi MP, Midia M, Chaudry G, Gemmete JJ, Mitchell JW, Brody L, Crowley JJ, Heran MKS, Weinstein JL, Nikolic B, Dariushnia SR, Tam AL, Venkatesan AM. Adult and Pediatric Antibiotic Prophylaxis during Vascular and IR Procedures: A Society of Interventional Radiology Practice Parameter Update Endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology.
J Vasc Interv Radiol. 2018 Nov;29(11):1483-1501.e2. [
PubMed: 30274857]
- 18.
Baerlocher MO, Nikolic B, Silberzweig JE, Kinney TB, Kuo MD, Rose SC., Society of Interventional Radiology. Society of Interventional Radiology position statement on recent change to the ASA's moderate sedation standards: capnography.
J Vasc Interv Radiol. 2013 Jul;24(7):939-40. [
PubMed: 23796081]
- 19.
Spies JB, Rundback JH, Ascher S, Bradley L, Goodwin SC, Hovsepian DM, Myers ER, Pelage JP, Pron G, Siskin GP, Stewart EA, Worthington-Kirsch R, Hume KM, Strain C, Gomolka B., SIR Foundation. Development of a research agenda for uterine artery embolization: proceedings from a multidisciplinary research consensus panel.
J Vasc Interv Radiol. 2006 Dec;17(12):1871-9. [
PubMed: 17185681]
- 20.
Nassiri N, Balica A, Cirillo-Penn NC, Crystal DT, Bachmann GA. An Academic Tertiary Referral Center's Experience with a Vascular Surgery-Based Uterine Artery Embolization Program.
Ann Vasc Surg. 2018 Oct;52:90-95. [
PubMed: 29777846]
- 21.
Stewart EA, Lytle BL, Thomas L, Wegienka GR, Jacoby V, Diamond MP, Nicholson WK, Anchan RM, Venable S, Wallace K, Marsh EE, Maxwell GL, Borah BJ, Catherino WH, Myers ER. The Comparing Options for Management: PAtient-centered REsults for Uterine Fibroids (COMPARE-UF) registry: rationale and design.
Am J Obstet Gynecol. 2018 Jul;219(1):95.e1-95.e10. [
PMC free article: PMC8889489] [
PubMed: 29750955]
- 22.
Gupta JK, Sinha A, Lumsden MA, Hickey M. Uterine artery embolization for symptomatic uterine fibroids.
Cochrane Database Syst Rev. 2014 Dec 26;(12):CD005073. [
PubMed: 25541260]
- 23.
de Bruijn AM, Ankum WM, Reekers JA, Birnie E, van der Kooij SM, Volkers NA, Hehenkamp WJ. Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 10-year outcomes from the randomized EMMY trial.
Am J Obstet Gynecol. 2016 Dec;215(6):745.e1-745.e12. [
PubMed: 27393268]
- 24.
Ananthakrishnan G, Murray L, Ritchie M, Murray G, Bryden F, Lassman S, Lumsden MA, Moss JG. Randomized comparison of uterine artery embolization (UAE) with surgical treatment in patients with symptomatic uterine fibroids (REST trial): subanalysis of 5-year MRI findings.
Cardiovasc Intervent Radiol. 2013 Jun;36(3):676-81. [
PubMed: 23070101]
- 25.
Namkung J, Kang SY, Chung YJ, Cho HH, Kim JH, Kim MR. Multidisciplinary Approach in Large-sized Submucosal Myoma: Hysteroscopic Myomectomy after Uterine Artery Embolization.
J Minim Invasive Gynecol. 2019 May-Jun;26(4):643-647. [
PubMed: 29969685]
- 26.
Schnapauff D, Russ M, Kröncke T, David M. Analysis of presurgical uterine artery embolization (PUAE) for very large uterus myomatosus; patient's desire to preserve the uterus; case series and literature review.
Rofo. 2018 Jul;190(7):616-622. [
PubMed: 29514385]
- 27.
Das CJ, Rathinam D, Manchanda S, Srivastava DN. Endovascular uterine artery interventions.
Indian J Radiol Imaging. 2017 Oct-Dec;27(4):488-495. [
PMC free article: PMC5761178] [
PubMed: 29379246]
- 28.
Borah BJ, Yao X, Laughlin-Tommaso SK, Heien HC, Stewart EA. Comparative Effectiveness of Uterine Leiomyoma Procedures Using a Large Insurance Claims Database.
Obstet Gynecol. 2017 Nov;130(5):1047-1056. [
PMC free article: PMC5683097] [
PubMed: 29016510]
Disclosure: Michael Young declares no relevant financial relationships with ineligible companies.
Disclosure: William Coffey declares no relevant financial relationships with ineligible companies.
Disclosure: Lyree Mikhail declares no relevant financial relationships with ineligible companies.
